Phosphogliv

1 capsule contains:

active substances :

Phospholipids (Lipoid C 80) (the main component of phosphatidylcholine 73-79%) - 65 mg,

sodium glycyrrhizinate (trisodium salt of glycyrrhizic acid) - 35 mg.

Excipients:

microcrystalline cellulose - 141.2 mg,

calcium carbonate - 204.7 mg,

calcium stearate - 0.9 mg,

talc - 7.7 mg

silicon dioxide colloidal (aerosil) - 5.5 mg.

Phosphogliv is a combined remedy. It has a membrane stabilizing, hepatoprotective and antiviral effect.

Phosphatidylcholine (the active substance of phospholipids) is the main structural element of cell and intracellular membranes, it is able to restore their structure and function in case of damage, having a cytoprotective effect. It normalizes protein and lipid metabolism, prevents the loss of enzymes and other active substances by hepatocytes, restores the detoxifying function of the liver, and inhibits the formation of connective tissue, reducing the risk of liver fibrosis and cirrhosis.

Glycyrate (glycyrrhizic acid and salts) has an anti-inflammatory effect, inhibits the reproduction of viruses in the liver and other organs by stimulating the production of interferons, increasing phagocytosis, and increasing the activity of natural killer cells. It has a hepatoprotective effect due to antioxidant and membrane stabilizing activity. It potentiates the action of endogenous glucocorticosteroids, providing an anti-inflammatory and anti-allergic effect in non-infectious liver lesions.

With skin lesions due to the membrane-stabilizing and anti-inflammatory action of the components, it limits the spread of the process and contributes to the regression of the disease.

Pharmacokinetics

The components of the drug are well absorbed in the intestine, both in the form of whole molecules and bioactive hydrolysis products (unsaturated fatty acids, choline, glycyrrhetic acid), which, after absorption through the intestinal walls, easily penetrate the liver, lungs, skin and other organs.

• Viral hepatitis (acute and chronic),
• fatty liver degeneration (hepatosis),
• other liver lesions (drug, alcohol, toxic),
• cirrhosis of the liver,
• intoxication
• psoriasis,
• neurodermatitis
• eczema.

The drug is contraindicated in pregnancy and lactation.

Hypersensitivity to the components of the drug Phosphogliv, pregnancy, lactation.

Precautions: in patients with portal hypertension.

With increased individual sensitivity, a skin rash may occur, which disappears after discontinuation of the drug.

The drug interaction of the drug Phosphogliv® is not described.

Phosphogliv is taken orally during meals, washed down with a small amount of liquid.

Adults and children over 12 years of age 1-2 capsules 3-4 times a day.

Currently, overdose of the drug Phosphogliv® was not observed.

In case of increased blood pressure, you should stop taking the drug and consult a doctor.

Influence on the ability to drive vehicles and mechanisms

The drug does not adversely affect the ability to drive vehicles and perform other work that requires an increased concentration of attention and speed of psychomotor reactions.

Capsules